CorMedix, Inc. (CRMD)
| Market Cap | 236.69M |
| Revenue (ttm) | 253,438 |
| Net Income (ttm) | -23.69M |
| Shares Out | 36.33M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $5.97 |
| Previous Close | $6.25 |
| Change ($) | -0.28 |
| Change (%) | -4.48% |
| Day's Open | 6.28 |
| Day's Range | 5.95 - 6.30 |
| Day's Volume | 136,289 |
| 52-Week Range | 3.86 - 18.80 |
New York, New York--(Newsfile Corp. - July 29, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD).Shar...
Los Angeles, California--(Newsfile Corp. - July 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CorMedix Inc. ("CorMed...
New York, New York--(Newsfile Corp. - July 29, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased CorMedix Inc. ("CorM...
NEW YORK, July 29, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a Lead Plaintiff motion in a securities class actio...
NEW YORK--(BUSINESS WIRE)-- #CRMD--Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against CorMedix Inc. (NASDAQ: CRMD) and September 20 Deadline
BENSALEM, Pa.--(BUSINESS WIRE)---- $CRMD #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CorMedix Inc. (“CorMedix” ...
LOS ANGELES--(BUSINESS WIRE)---- $CRMD #investors--The Law Offices of Frank R. Cruz Announces Investigation of CorMedix Inc. (CRMD) on Behalf of Investors
New York, New York--(Newsfile Corp. - July 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that t...
NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and certain of its officers....
New York, New York--(Newsfile Corp. - July 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CorM...
SAN DIEGO--(BUSINESS WIRE)---- $CRMD #CRMD--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of CorMedix Inc. (NASDAQ: CRMD) between July ...
LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...
BENSALEM, Pa.--(BUSINESS WIRE)---- $CRMD #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) investors concern...
BERKELEY HEIGHTS, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...
San Diego, California--(Newsfile Corp. - July 27, 2021) - The CorMedix class action lawsuit charges CorMedix Inc. (NASDAQ: CRMD) and certain of its top executives with violations of the Securities Excha...
LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CRMD--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc.
NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CorMedix Inc. ...
New York, New York--(Newsfile Corp. - July 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that ...
LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CRMD--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc.
New York, New York--(Newsfile Corp. - July 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cor...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD...
NEW YORK, July 26, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or "the...
SAN DIEGO, July 26, 2021 /PRNewswire/ -- The CorMedix class action lawsuit charges CorMedix Inc. (NASDAQ: CRMD) and certain of its top executives with violations of the Securities Exchange Act of 1934 a...
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against CorMedix Inc. (“CorMedix” or the...
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers of CorMedix Inc. (NASDAQ: CRMD) securities between July 8, 2020 and May 13, 2021, inclusive (“Class Period”) have u...
New York, New York--(Newsfile Corp. - July 23, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of i...
NEW YORK, July 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and certain of its officers....
BERKELEY HEIGHTS, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...
BERKELEY HEIGHTS, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...
BERKELEY HEIGHTS, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and t...
Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...
CorMedix (CRMD) delivered earnings and revenue surprises of -11.11% and 46.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
Thomas Nusbickel to join CorMedix as Chief Commercial Officer; Brings significant experience in renal product launches and commercialization Thomas Nusbickel to join CorMedix as Chief Commercial Officer...
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BERKELEY HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to contac...
BERKELEY HEIGHTS, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to conta...
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to cont...
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. (NASDAQ: CRMD) are among the biggest movers among health care stocks Tuesday.
BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA gave a thumbs-down to CorMedix's antibacterial/anti-fungal catheter lock.
The FDA has issued a Complete Response Letter for CorMedix Inc's (NASDAQ: CRMD) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-related blo...
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology... [Read more...]
| Industry Biotechnology | IPO Date Mar 25, 2010 |
| CEO Khoso Baluch | Employees 35 |
| Stock Exchange NASDAQ | Ticker Symbol CRMD |
Financial Performance
In 2020, CorMedix's revenue was $239,231, a decrease of -15.55% compared to the previous year's $283,266. Losses were -$22.03 million, 34.0% more than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for CorMedix stock is "Buy." The 12-month stock price forecast is 20.30, which is an increase of 240.03% from the latest price.